Trajenta

📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.

Why order from MedsBase

Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.

What Is Trajenta?

Trajenta is an oral antidiabetic medicine containing linagliptin (5 mg), manufactured by Boehringer Ingelheim. Available in packs of 30, 60, 90 or 180 tablets. It is prescribed for adults with type 2 diabetes, usually alongside metformin or as a second- or third-line agent.

linagliptin belongs to the DPP-4 inhibitor (“gliptin”) class — first approved 2011 (originator brand: Trajenta, Boehringer Ingelheim / Eli Lilly). Gliptins are widely used because they are weight-neutral, have a low hypoglycaemia risk, and can be used across the renal spectrum with appropriate dose adjustment.

How Does Trajenta Work?

After meals, the gut releases two incretin hormones — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones tell the pancreas to release insulin and the liver to suppress glucagon, but they are rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4) within minutes.

linagliptin blocks DPP-4. This raises active GLP-1 and GIP levels, producing:

• Glucose-dependent insulin release from pancreatic beta cells — only when blood glucose is elevated
• Suppression of glucagon from alpha cells, reducing hepatic glucose output after meals
• Modest slowing of gastric emptying

Because insulin release is glucose-dependent, DPP-4 inhibitors do not cause hypoglycaemia on their own. Typical HbA1c reduction: 0.6–0.8 percentage points. Weight effect: neutral. Blood pressure and lipid effects: neutral.

Dosage and Administration

Standard dose: 5 mg once daily — one fixed dose regardless of renal or hepatic function. Trajenta can be taken with or without food.

• Once-daily dosing (twice for vildagliptin) — pick a consistent time.
• Half-life and excretion: > 100 hours (long terminal half-life); ~80% excreted unchanged via the biliary/faecal route — only about 5% renal.
• Renal dosing: No dose adjustment needed at any eGFR — linagliptin is the DPP-4 of choice for CKD, including dialysis.
• No hepatic dose adjustment for most gliptins (vildagliptin needs baseline ALT check).
• Miss a dose — skip it; take the next at the usual time. Do not double up.

Side Effects

DPP-4 inhibitors are among the best-tolerated oral antidiabetics. Most side effects are mild and similar across the class.

Common:

• Upper respiratory tract infection, nasopharyngitis
• Headache
• Mild GI upset — nausea, diarrhoea (less common than with metformin)

Uncommon but important:

• Acute pancreatitis — rare but documented class effect; stop immediately if severe abdominal pain develops
• Severe joint pain (arthralgia) — can occur weeks to months after starting; usually resolves on discontinuation
• Hypersensitivity / angioedema — bullous pemphigoid has been reported; stop if blistering skin lesions develop
• Saxagliptin specifically: small increase in hospitalisation for heart failure
• Vildagliptin specifically: rare hepatic enzyme elevations — monitor ALT

As monotherapy, hypoglycaemia is very rare. When combined with sulfonylureas or insulin, those agents’ doses may need reducing.

Drug Interactions

• Sulfonylureas, insulin, meglitinides — additive glucose-lowering. Expect to reduce these doses when adding a gliptin.
• Strong CYP3A4/5 inhibitors (ketoconazole, clarithromycin, ritonavir, atazanavir) — raise saxagliptin levels; halve the saxagliptin dose. Minimal effect on sitagliptin, linagliptin, vildagliptin.
• Rifampicin — reduces linagliptin levels modestly; effect may be clinically meaningful.
• ACE inhibitors — theoretical additive angioedema risk; clinical significance debated.
• Digoxin — small rise in peak level with sitagliptin; usually not clinically important.

Who Should Not Take Trajenta?

• Type 1 diabetes mellitus
• Diabetic ketoacidosis
• Known hypersensitivity to linagliptin or other DPP-4 inhibitors
• History of pancreatitis (relative — discuss alternatives)
• Pregnancy and breastfeeding — data limited; alternatives preferred
• Saxagliptin specifically: severe heart failure
• Vildagliptin specifically: ALT or AST > 3× upper limit of normal

Storage

Store Trajenta below 30°C in a dry place, in the original blister. Keep out of reach of children.

Frequently Asked Questions

Is Trajenta the same as linagliptin?

Yes. Trajenta contains the same active ingredient as the originator brand. Bioequivalence is required by regulatory authorities, so clinical effect is the same at the same dose.

Why choose linagliptin over sitagliptin?

Linagliptin’s main advantage is that it does not need dose adjustment in kidney disease — the same 5 mg tablet works whether eGFR is 90 or 15. Sitagliptin has a larger outcome-trial dataset but requires 50% or 75% dose cuts in moderate-to-severe CKD. For patients with stable renal function, the two are clinically similar.

Will Trajenta cause low blood sugar?

On its own, no. DPP-4 inhibitors act in a glucose-dependent manner — they only augment insulin release when blood glucose is high. Hypoglycaemia only becomes a concern when Trajenta is combined with a sulfonylurea, meglitinide, or insulin.

Does Trajenta cause weight gain?

No — DPP-4 inhibitors are weight-neutral. This is one of the main reasons they are preferred over sulfonylureas in overweight patients.

Can Trajenta cause pancreatitis?

Acute pancreatitis is a rare but documented class effect. The absolute risk is small, and large trials (TECOS, CARMELINA, SAVOR) have generally shown no statistically significant excess. Stop immediately and seek medical attention if severe abdominal pain develops — especially pain radiating to the back.

How long does Trajenta take to work?

Fasting glucose starts to fall in the first week. Maximal HbA1c effect is at 12 weeks. If HbA1c has not fallen by at least 0.3–0.5% after 3 months, a different second agent (SGLT-2 inhibitor or GLP-1 agonist) should be considered.

Can I stop Trajenta suddenly if I don’t feel well?

Yes — DPP-4 inhibitors can be stopped abruptly without rebound hyperglycaemia. If you develop severe abdominal pain, skin blistering, or severe joint pain, stop and contact your doctor.

Where can I buy Trajenta online?

You can order Trajenta (5 mg) from MedsBase in packs of 30, 60, 90 or 180 tablets. We ship worldwide, with discreet packaging and genuine WHO-GMP certified manufacturer stock.

Related Diabetes Medications

• Januvia — Sitagliptin 25/50/100 mg (Merck)
• Trajenta — Linagliptin 5 mg (Boehringer Ingelheim)
• Galvus — Vildagliptin 50 mg (Novartis)
• Janumet — Sitagliptin + Metformin combo
• Jardiance — Empagliflozin (SGLT-2 alternative)
• Glycomet SR — Metformin sustained-release
• Browse all Diabetes Medications

More options in Diabetes

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Glinate

US$13.00 – US$33.00Prijsbereik: US$13.00 tot US$33.00

Daonil

US$5.00 – US$12.00Prijsbereik: US$5.00 tot US$12.00

Glucobay

US$8.00 – US$31.00Prijsbereik: US$8.00 tot US$31.00